We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Machine Learning Models Help Predict Heart Disease Risk in Women

By HospiMedica International staff writers
Posted on 25 Apr 2024

In the field of cardiac health, cardiovascular disease is notably underdiagnosed in women compared to men. More...

The commonly used Framingham Risk Score, which predicts the likelihood of developing cardiovascular disease within the next 10 years, is based on specific criteria including age, sex, cholesterol levels, and blood pressure. However, this does not account for anatomical differences between sexes; female hearts, for example, are typically smaller and have thinner walls. Consequently, using the same diagnostic standards for both sexes means that women's hearts need to increase disproportionally more than men’s to meet the same risk criteria. A team of researchers has now built more accurate cardiovascular risk models than the Framingham Risk Score using a large dataset and have also quantified the underdiagnosis of women compared to men.

Researchers at Stanford University (Stanford, CA, USA) quantified the underdiagnosis of women compared to men and found that the use of sex-neutral criteria results in significant underdiagnosis of female patients. To achieve more accurate predictions for both sexes, they incorporated four additional metrics absent in the Framingham Risk Score: cardiac magnetic resonance imaging, pulse wave analysis, EKGs, and carotid ultrasounds. Utilizing data from over 20,000 individuals in the UK Biobank—a comprehensive biomedical database of around half a million UK residents aged 40 and over—they applied machine learning techniques. They found that EKGs were particularly effective in enhancing cardiovascular disease detection in both sexes. Despite this, traditional risk factors remain valuable for assessing risk, according to the researchers.

This study marks the first step towards reevaluating risk factors for heart disease by incorporating advanced technologies to improve risk prediction. Nevertheless, the study faces limitations that future research should address. One such limitation is the binary treatment of sex in the UK Biobank, ignoring the complex nature of sex involving hormones, chromosomes, and physical traits that may not fit neatly into 'male' or 'female' categories. Moreover, the study's focus on middle-aged and older UK residents may limit the applicability of the findings to other demographic groups and geographical locations.

“We found that that sex-neutral criteria fail to diagnose women adequately. If sex-specific criteria were used, this underdiagnosis would be less severe,” said Skyler St. Pierre, a researcher at Stanford University's Living Matter Lab. “We also found the best exam to improve detection of cardiovascular disease in both men and women is the electrocardiogram (EKG).”

“While traditional clinical models are easy to use, we can now use machine learning to comb through thousands of other possible factors to find new, meaningful features that could significantly improve early detection of disease,” added St. Pierre.

Related Links:
Stanford University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.